more, significant removal of parvoviruses can be achieved using nanofilters with mean pore sizes of 15 nm. 10 This report describes a virus inactivation method consisting of a pasteurization performed in the presence of 3 M guanidine hydrochloride (GdnHCl). Apolipoprotein A-I (apoA-I) isolated from human plasma can be subjected to such pasteurization. 11 The pasteurized apoA-I can be readily reconstituted in an active form suitable for therapeutic use. 12 The virus inactivation achieved by the pasteurization of apoA-I was validated using minute virus of mice (MVM), bovine enterovirus (BEV), Sindbis virus (Sin), pseudorabies virus (PRV ), and HIV-1 as models for human parvovirus B19, hepatitis A virus, hepatitis C virus, human herpesviruses, and HIV-1/2, respectively.
MATERIALS AND METHODS

Viruses and cells
Viruses and cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) or from European Collection of Cell Cultures (ECACC, Salisbury, Wiltshire, UK) unless stated otherwise. MVM (prototype, ATCC number VR-1346) was propagated on A9 cells. BEV (type 2, strain V100/60) was obtained from the Veterinary School, University of Bern (Bern, Switzerland) and grown on Vero cells. Sin (wild type) was a gift from Milton Schlesinger, MD, Washington University School of Medicine (St. Louis, MO) and grown on Aedes albopictus cells. PRV (strain Aujeszky, ATCC number VR-135) was propagated as described elsewhere. 13 HIV-1 (strain Bru) was obtained from GeorgSpeyer-Haus (Frankfurt, Germany) and propagated on C 8166-45 cells.
A9 cells (ECACC number 85011426) were grown in DMEM supplemented with 10 percent fetal calf serum (FCS). C 8166-45 cells (derived from umbilical cord blood lymphocytes, HTLV-I transformed), were obtained from Georg-Speyer-Haus and cultivated in RPMI 1640 medium supplemented with 5 percent FCS. Bovine turbinate (BT) cells (ATCC number CRL-1390), Vero cells (ATCC number CCL 81), and Aedes albopictus cells, clone C6/36, obtained from Sonja Buckley, PhD, Yale University Arbovirus Research Unit, New Haven, CT) were cultivated as described elsewhere. S]cysteine (NEN Life Science Products, Boston, MA), from 3.5 to 4.5 hours after infection, followed by an incubation of 50 minutes in the absence of radiolabel. Subsequently, the cells were lysed with 1 percent Nonidet P-40 in RS8 (10 mM NaCl, 10 mM Tris, pH 7.5) and nuclei were removed by centrifugation at 1000 × g for 15 minutes. SDS was added to the postnuclear supernatant (PNS) to a final concentration of 0.5 percent. The SDS-containing PNS was layered on top of 30 percent (wt/wt) sucrose in RS8 and the virus was pelleted at 53,900 × g for 17 hours. Pelleted virus was resuspended in DMEM containing 2 percent FCS, aliquoted, and frozen at -70°C. Radiolabeled protein was precipitated with trichloroacetic acid (TCA) and characterized by SDS-PAGE followed by autoradiography.
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Determination of virus titers and reduction factors
MVM titers were determined on A9 cells. Sin was quantified on Vero cells. BEV and PRV titers were measured on BT cells. HIV-1 titers were determined on C 8166-45 cells. Virus infectivity was measured by endpoint titration in 96-well microplates (eight wells per dilution). Tissue culture infectious doses-50 percent (TCID 50 ) were calculated using the method of Spearman and Kärber as described by regulatory authorities.
15 Virus titers were expressed as log (TCID 50 per mL). If desirable, the limits of detection were reduced by testing larger sample volumes in tissue culture flasks or 96-well microplates (bulk assays). Low virus concentrations (i.e., titers when no virus was detectable), logarithmic reduction factors (log RF), and 95 percent CIs were determined according to regulatory guidelines.
15,16
Preparation and pasteurization of apoA-I
The isolation and pasteurization of apoA-I has been described previously. 11 Briefly, apoA-I is purified from human plasma using cold ethanol precipitations. Precipitates containing delipidated apoA-I and filter aid (Celite) are resuspended with three volumes of 4 M GdnHCl and 1 mM EDTA (pH 5.2), resulting in final concentrations of 3 M GdnHCl, 0.75 mM EDTA, and 2.5 percent apoA-I. These suspensions are pasteurized at 60°C. After the pasteurization, the pH is adjusted to 7.5, the filter aid is removed, and the system is desalted by gel filtration (Sephadex G-25, Amersham Pharmacia Biotech, Uppsala, Sweden), resulting in solutions containing 0.9 percent apoA-I.
In the present study, material from two different production steps was used, namely, apoA-I suspensions prepared for pasteurization and apoA-I obtained after gel filtration.
For virus validations, apoA-I suspensions prepared for pasteurization were spiked with the different model viruses and incubated at 60°C. Pasteurizations under these conditions are referred to as standard apoA-I pasteurizations in this study. Other conditions were used in experiments involving temperature-and GdnHCl-concentration dependence and for the determination of the virus inactivation mechanism using radiolabeled enterovirus. Temperaturedependence studies and the experiments with radiolabeled enterovirus were performed with apoA-I suspensions prepared for pasteurization but in the absence of a filter aid, which was removed by centrifugation before virus spiking. GdnHCl-concentration-dependence experiments were performed with 0.9 percent apoA-I obtained after gel filtration, which was resupplemented with GdnHCl to defined concentrations and adjusted to pH 7.0 before the addition of virus.
Desalting of virus-containing samples using size exclusion chromatography
In most experiments, GdnHCl was removed from the samples before virus titration. Virus-containing samples were withdrawn from the pasteurization process and immediately diluted with ice-cold cell culture medium. Disposable PD-10 size exclusion chromatography columns (Pharmacia Biotech, Uppsala, Sweden) were equilibrated with PBS and 1 mL of the diluted samples was added to the column. Fractions of 3 mL were collected and used for virus titer determinations. Recoveries of viral infectivity after size exclusion chromatography were between 45 and 100 percent for all viruses used in this study, whereas GdnHCl was reduced to concentrations not interfering with cell proliferation and virus replication.
Sedimentation analysis of radiolabeled BEV
ApoA-I solutions were spiked with purified, radiolabeled BEV. After incubations at 60°C or on ice, the spiked solutions were diluted with RS8 and 1 mL was loaded onto 14 mL of linear 15 to 30 percent (wt/wt) sucrose gradients in PBS. Radiolabeled virus was sedimented at 92,900 × g for 210 minutes. Fractions of 1 mL were collected from the sucrose gradients and analyzed by liquid scintillation.
Pasteurization of albumin in the presence of GdnHCl
Solutions of 5 percent human albumin (Albumin 5% SRK, ZLB Central Laboratory, Bern, Switzerland) were diluted fivefold with 0.9 percent NaCl. GdnHCl was added to the desired concentration and the solutions were adjusted to pH 5.5. These solutions were pasteurized at 60°C for the times indicated and GdnHCl was subsequently removed by size-exclusion chromatography. These conditions did not alter isoelectric focusing patterns of the protein compared with commercially available pasteurized albumin.
RESULTS
Inactivation kinetics of BEV and MVM during pasteurization of apoA-I
The present study was initiated to evaluate whether pasteurization for 10 hours at 60°C in the presence of 3 M GdnHCl inactivates plasma-relevant viruses including parvo-and enteroviruses. The model viruses MVM and BEV were spiked separately into apoA-I suspensions and the spiked systems were incubated at 60°C under standard apoA-I pasteurization conditions or, as controls, on ice. Samples were taken at different times, GdnHCl was removed by size-exclusion chromatography, and virus titers were determined. The resulting virus inactivation kinetics are shown in Fig.1 . Both model viruses were inactivated at 60°C, whereas incubations on ice did not reduce the respective viral titers. BEV was inactivated much faster than MVM, illustrating the high physicochemical stability of the parvovirus. In all standard apoA-I pasteurization experiments performed, however, MVM was inactivated to levels below detection limit within 10 hours at 60°C.
Reduction factors achieved for different model viruses
The pasteurization of apoA-I was further validated with a series of other viruses accepted as models for transfusionrelevant viruses. Sin, PRV, and HIV-1 were used as additional model viruses. The results are summarized in Table 1 . All model viruses were inactivated to titers below the limit of detection upon pasteurization of apoA-I. The inactivation of PRV and HIV-1 was so fast that immediately after spiking of ice-cold apoA-I suspensions, no infectious virus was recovered. Artifacts such as high-affinity binding of the virus to the filter aid or significant virus loss on the size-exclusion column could be excluded by spiking control systems composed of cell culture medium containing filter aid 
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Volume 41, March 2001 TRANSFUSION 385 www.transfusion.org but no GdnHCl and by determining the respective viral titers after size-exclusion chromatography. Inactivation of HIV by chaotropic agents was also demonstrated by others using sodium thiocyanate in the production of factor IX. 17 Similar to PRV and HIV-1, Sin was also inactivated in icecold apoA-I suspensions, but at a much slower rate than the herpes-and retrovirus. The inactivation of Sin in the icecold suspensions may be, at least partially, a result of the relatively low pH of 5.2, as Sin infectivity decreases when the virus is incubated at a pH of 5.6 or lower.
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Temperature dependence and GdnHClconcentration dependence of virus inactivation
The presence of GdnHCl alone is not sufficient to inactivate parvo-and enteroviruses, as no virus inactivation was seen in apoA-I suspensions kept on ice (Fig. 1) . This suggested that the combination of GdnHCl and heat executed the virus-inactivating effect. Both factors were tested separately. Solutions containing apoA-I prepared for pasteurization were prewarmed to different temperatures and spiked with BEV. The resulting virus inactivation kinetics were clearly temperature dependent (Fig. 2) . At 45°C a transient virus titer increase was observed, most probably reflecting fast dissociation of virus aggregates followed by slow temperature-induced virus inactivation.
The influence of the GdnHCl concentration on virus inactivation was tested using apoA-I obtained after gel filtration, which was resupplemented with different amounts of GdnHCl. The gel filtrate was used because apoA-I routinely prepared for pasteurization caused technical problems when pasteurized in a wide range of GdnHCl concentrations. The apoA-I gel filtrates containing different concentrations of GdnHCl were equilibrated at 60°C and subsequently spiked with MVM. Inactivation kinetics are shown in Fig. 3 . Almost no inactivation was seen in the absence of GdnHCl at 60°C, at least during the time tested (6 hours). A clear increase in inactivation rate was seen with increasing GdnHCl concentration. In 4 M GdnHCl at 60°C, MVM titers were reduced by more than 3 log units within 15 minutes.
Sedimentation analysis of radiolabeled BEV after apoA-I pasteurization
The mechanism of virus inactivation during pasteurization in GdnHCl-containing protein solutions was explored by using radiolabeled and purified enterovirus. BEV proteins were labeled metabolically with [
35 S]amino acids (methionine and cysteine) and virus particles were purified by a single-step sucrose centrifugation. Virus particle proteins found in the pellet were visualized by SDS-PAGE and autoradiography. Enteroviruses are composed of four capsid proteins (VP1, VP2, VP3, and VP4) that have apparent molecular weights of approximately 38 kDa, 34 kDa, 30 kDa, and <10 kDa, respectively. 19 Enteroviral protein VP4 is often not visible after the labeling and visualization procedure used in this study, either because of its low molecular weight or because of the absence of methionine and cysteine in this protein. The three proteins visible on the autoradiograph (Fig. 4A ) had apparent molecular weights in the range of VP1, VP2, and VP3, which, together with the sedimentation behavior of intact virus in sucrose gradients (see below), showed that radiochemically pure virus particles were isolated.
Purified radiolabeled BEV was spiked into solutions containing apoA-I prepared for pasteurization and the solutions were incubated at 60°C or on ice. After the incubation, the integrity of the virus particles was analyzed by sucrose gradient centrifugation (Fig. 4B) . After incubations on ice, intact virus was found in fraction 6 and adjacent fractions. These fractions contain the peak of enteroviral infectivity as confirmed by TCID 50 analysis and as published elsewhere. 20 On the other hand, this peak around fraction 6 was completely missing after incubations at 60°C. After the incubation at 60°C, however, a relative increase in radioactivity was found in the top fraction of the gradient where single proteins or slowly sedimenting subviral particles would be expected. These results indicate that the integrity of enterovirus particles is destroyed during pasteurization of apoA-I in the presence of GdnHCl. * Standard apoA-I pasteurization as described in Material and Methods; control = corresponding cell culture medium, pH 5.2, supplemented with filter aid (Celite). † Titers (± 95% CI) as determined after desalting by size-exclusion chromatography. Titers after exposure at 0°C were determined by endpoint titration and after incubation at 60°C by bulk assays. The titers in the apoA-I system are average values of two experiments for BEV, Sin, and PRV and of three determinations for MVM and HIV-1. ‡ The logarithmic reduction factor (± 95% CI) achieved by pasteurization at 60°C; i.e., the difference between the initial titer (0 minutes) at 0°C and the titer after the indicated exposure at 60°C. § No virus was detected. The indicated titer corresponds to the detection limit of the experiment, which was 1.9 and 0.0 log units per mL for endpoint titrations and bulk assays, respectively. www.transfusion.org
MVM inactivation during pasteurization of albumin in the presence of GdnHCl
Temperature-and GdnHCl-concentration-dependent virus inactivation was observed during apoA-I pasteurization. In order to test whether virus inactivation would also occur in solutions of proteins other than apoA-I, albumin was pasteurized in the presence of GdnHCl. Solutions of 1 percent human albumin were supplemented with different concentrations of GdnHCl, spiked with MVM, and incubated at 60°C. A time-and GdnHCl-concentration-dependent inactivation of MVM was observed (Fig. 5) . This experiment demonstrated that virus inactivation also takes place when a protein other than apoA-I is pasteurized in the presence of molar concentrations of GdnHCl. The MVM inactivation kinetics obtained during these albumin pasteurizations, however, are not directly comparable to MVM inactivation rates observed during apoA-I pasteurizations due to differences in the composition of the respective systems.
DISCUSSION
Validations of virus inactivating manufacturing steps have to demonstrate inactivation kinetics. 15, 16 Kinetics of virus inactivation are indicative of the potency of an inactivation step. Pasteurization is a classic virus inactivation step and has been shown to be efficient for most viruses. When pasteurization is performed with the final components to be used for transfusion, however, it often fails to completely inactivate parvoviruses.
2, 21 One potential rationale for this observation is that these pasteurizations are usually performed in the presence of protein stabilizers that may also stabilize viruses.
We have developed a reconstituted high-density lipoprotein product, 11 the protein moiety of which is pasteurized for 10 hours at 60°C in the presence of 3 M GdnHCl. The present study demonstrated that viruses representing a wide range of physicochemical stability are efficiently inactivated under these conditions. Members of the virus families retro-, herpes-, toga-, picorna-, and parvoviridae were inactivated to levels below the detection limit within 10 hours at 60°C. Inactivation kinetics in the apoA-I system, however, were clearly different for the five model viruses tested. At 60°C, the inactivation of MVM (parvovirus) was slower than the inactivation of BEV (picornavirus). When the apoA-I system was kept on ice, the inactivation of Sin (togavirus) was slower than the inactivation of PRV (herpesvirus) and HIV-1 (retrovirus). The results of this study show that the physicochemical stability of the tested viruses with respect to the pasteurization analyzed decreased in the following order: MVM > BEV > Sin > PRV, HIV-1.
The mechanism of virus inactivation was demonstrated using sedimentation analysis. BEV, which was used as a model in these experiments, disintegrated into noninfectious subunits upon pasteurization in the apoA-I system. GdnHCl itself did not induce BEV disassembly as the virus retained its native particle integrity when the system was kept on ice. The combination of both GdnHCl and heat led to virus particle disintegration. Such combinations of chaotropic reagents and elevated temperatures are known to induce protein unfolding. In this context it seems plausible that virus particles are disassembled into smaller subunits during pasteurization in the presence of molar concentrations of GdnHCl.
Virus inactivation that results from virus particle disassembly does not depend on chemical modification of macromolecules, which is a requirement in inactivation methods based on ethyleneimine, β-propiolactone, or iodine. The pasteurization in the presence of chaotropic reagents, therefore, is potentially less harmful to the protein of interest than methods depending on chemical modification, provided the therapeutic protein can be refolded in an active form. ApoA-I, compared with other plasma-derived therapeutic proteins, is a small protein composed of 243 amino acids that contains neither disulfide bonds nor carbohydrate side chains. 22 The refolding and reconstitution of this protein, therefore, are relatively simple. However, proteins other than apoA-I, especially if they have complicated tertiary structures or if they form higher oligomeric complexes, might be more difficult to functionally recover from GdnHCl-containing and pasteurized solutions.
The transmission of parvovirus B19 was demonstrated clinically for some preparations of human clotting factor concentrates, even if the components were inactivated with steam heat, dry heat, or by pasteurization. 21 Using PCR technology with recombinant FVIII produced in genetically engineered animal cells was found to contain parvovirus B19 DNA, 23 and parvovirus B19 transmission with recombinant FVIII may have occurred. 24 Albumin purified from human plasma, which is often used as a stabilizing agent in these components, might be the source of the contamination. Indeed, there is evidence that parvovirus B19 DNA might be present in albumin derived from human blood. 25 PCR technology could be used to reduce the risk of parvovirus B19 contaminations in end components. Because of its specificity, the PCR approach, however, would not detect other viruses potentially present in the plasma or the end product. There are, in fact, small, nonenveloped viruses other than parvovirus B19 that might be present in human blood, such as the recently discovered TT virus, which seems to be the first human member of the virus family circoviridae. 26, 27 A potential risk for TT virus transmission by blood components arises from the finding that TT virus DNA was found in FVIII, Factor IX, and immunoglobulin components. 28 The transmission of parvovirus B19 upon treatment with coagulation factors and the emergence of new, small, nonenveloped viruses such as TT virus show the need to develop inactivation technologies with the capacity to inactivate parvovirus and other small nonenveloped viruses. Pasteurization in the presence of GdnHCl has the potential to fulfill this task. ApoA-I is an example of a protein that can be pasteurized under such conditions and can be recovered in an active form after the pasteurization. Other proteins as well might be pasteurized in the presence of GdnHCl, provided they can be refolded in a form suitable for therapeutic use.
